Laboratoire de Neurobiologie OroFaciale (LabNOF, EA7543), Service Odontologie, Université Paris Cité, Groupe Hospitalier Pitié Salpêtrière-APHP, 47-83 Bd de l'Hôpital, 75651, Paris Cedex 13, France.
GHPS Assistance Publique Hôpitaux de Paris, Paris, France.
Sci Rep. 2023 Sep 19;13(1):15533. doi: 10.1038/s41598-023-42051-y.
The aim of this meta-analysis was to answer the following question: "Are there any differences in opiorphin biomarker concentrations between different orofacial conditions and controls?". Two reviewers searched for observational studies that evaluated the levels of opiorphin in orofacial conditions, annotated in seven main databases and three that compile gray literature. Of the 443 articles obtained initially, 8 met the inclusion criteria for quantitative analyses. Relative percentages showed a mean 24.1% higher opiorphin concentration in chronic conditions (Burning Mouth Syndrome, Oral Potentially Malignant Diseases and Temporomandibular Disorder) compared to controls; 33.2% higher opiorphin in sustained pain (Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis, Painful Oral Soft-tissue conditions); and 21.7% higher opiorphin after stimuli (Corneal Foreign Body, Capsaicin). Meta-analysis revealed a standardized mean difference of 0.62 [0.02, 1.22] in the absolute concentration of opiorphin in saliva for the chronic group compared to the control. The analogous values for the sustained group and the stimulated group were 2.24 [0.34, 4.14] and 0.43 [0.00, 0.85], respectively. No differences in opiorphin levels were found for 'after Local Anesthesia before Tooth Extraction' or for apicoectomy. Based on the available evidence, in general, a statistically higher level of opiorphin is found in orofacial conditions. Salivary opiorphin levels are elevated in chronic, persisted and acute pain conditions, presumably reflecting a physiological homeostatic adaptative response to different conditions such as stress or pain. Salivary opiorphin might therefore be used as a valuable biomarker in several oral disorders.
“不同的口腔状况与对照相比，阿片啡肽生物标志物的浓度是否存在差异？”。两位审稿人检索了评估口腔状况中阿片啡肽水平的观察性研究，这些研究在七个主要数据库和三个汇编灰色文献的数据库中进行了标注。最初获得的 443 篇文章中，有 8 篇符合定量分析的纳入标准。相对百分比显示，慢性疾病（灼口综合征、口腔潜在恶性疾病和颞下颌关节紊乱）的阿片啡肽浓度平均高出 24.1%；持续性疼痛（症状性不可逆牙髓炎、症状性根尖周炎、口腔软组织疼痛性疾病）的阿片啡肽浓度高出 33.2%；刺激后（角膜异物、辣椒素）的阿片啡肽浓度高出 21.7%。荟萃分析显示，与对照组相比，慢性组唾液中阿片啡肽的绝对浓度的标准化均数差为 0.62 [0.02, 1.22]。持续组和刺激组的类似值分别为 2.24 [0.34, 4.14]和 0.43 [0.00, 0.85]。在“局部麻醉拔牙前”或根尖切除术的情况下，阿片啡肽水平没有差异。基于现有证据，一般来说，口腔状况中阿片啡肽的水平普遍较高。慢性、持续和急性疼痛状况下唾液中的阿片啡肽水平升高，推测反映了对不同状况（如压力或疼痛）的生理稳态适应性反应。因此，唾液中的阿片啡肽可能被用作几种口腔疾病的有价值的生物标志物。
